FSTL1 Polyclonal Antibody, APC Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-6050R-APC |
| Product Name | FSTL1 Polyclonal Antibody, APC Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog, Cow, Horse, Chicken, Rabbit |
| Specifications | |
| Conjugation | APC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human FSTL1/FRP |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 11167 |
| Subcellular location | Secreted |
| Synonyms | FSTL1; TSC-36; Follistatin like 1; Follistatin related protein; Follistatin-like protein 1; Follistatin-related protein 1; FRP; FSL1; FSTL1; FSTL1_HUMAN. |
| Background | TSC-36 is a secreted extracellular glycoprotein. The amino acid sequence of TSC-36 is similar to follistatin, an inhibitor of activin, as it contains a follistatin module. TSC-36 is a heparin-binding protein suggested to have a role in the negative regulation of cellular growth, as its expression is induced in response to TGF-b1. In addition, TSC-36 is not found in small cell lung cancer (SCLC) cells, a highly aggressive neoplasm, but is detected in some non-small cell lung cancer (NSCLC) cells, a moderately aggressive neoplasm.. May modulate the action of some growth factors on cell proliferation and differentiation. Binds heparin. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |